HighTower Advisors
BCRX icon

HighTower Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

HighTower Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
20,023
+624
+3% +$5.64K ﹤0.01% 3543
2026
Q1 		$185K Buy
19,399
+1,369
+8% +$10.6K ﹤0.01% 3511
2025
Q4 		$141K Buy
18,030
+930
+5% +$6.72K ﹤0.01% 3455
2025
Q3 		$130K Buy
17,100
+100
+0.6% +$833 ﹤0.01% 3490
2025
Q2 		$152K Sell
17,000
-61
-0.4% -$568 ﹤0.01% 3382
2025
Q1 		$128K Sell
17,061
-539
-3% -$4.35K ﹤0.01% 3309
2024
Q4 		$132K Sell
17,600
-1,459
-8% -$11.1K ﹤0.01% 3310
2024
Q3 		$146K Sell
19,059
-1,091
-5% -$8.29K ﹤0.01% 3223
2024
Q2 		$124K Buy
20,150
+2,000
+11% +$11K ﹤0.01% 3154
2024
Q1 		$92K Hold
18,150
– – ﹤0.01% 3166
2023
Q4 		$109K Buy
18,150
+201
+1% +$1.17K ﹤0.01% 3178
2023
Q3 		$126K Sell
17,949
-651
-4% -$4.68K ﹤0.01% 3043
2023
Q2 		$131K Buy
+18,600
New +$149K ﹤0.01% 3009
2021
Q1 		– Sell
-25,726
Closed -$191K – 3059
2020
Q4 		$191K Buy
+25,726
New +$133K ﹤0.01% 2211
2014
Q4 		– Sell
-13,000
Closed -$127K – 1589
2014
Q3 		$127K Buy
+13,000
New +$159K ﹤0.01% 1413

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

HighTower Advisors's BCRX Position: Q2 2026 in Review

HighTower Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 3.2% in Q2 2026, buying an estimated $5.64K and bringing the position to 20,023 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #3543.

HighTower Advisors first reported a position in BCRX in Q3 2014 and has held it in 15 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • HighTower Advisors held 20,023 shares of BioCryst Pharmaceuticals worth $200K as of Q2 2026.
  • HighTower Advisors bought 624 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $5.64K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3543 holding.
  • HighTower Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2014 and has held it in 15 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.